NovaBridge Biosciences (NBP) Current Deferred Revenue (2018 - 2023)

NovaBridge Biosciences (NBP) has 6 years of Current Deferred Revenue data on file, last reported at $305552.3 in Q4 2023.

• Quarterly Current Deferred Revenue fell 74.96% year-over-year to $305552.3 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $305552.3 (down 74.96% YoY) and the FY2023 annual result came in at $600000.0, down 99.95% from the prior year.
• Current Deferred Revenue declined to $305552.3 in Q4 2023 per NBP's latest filing, from $1.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $35.0 billion in Q4 2021 and bottomed at -$2.0 million in Q3 2019.
• The 5-year median for Current Deferred Revenue is $1.1 million (2020), against an average of $3.2 billion.
• The widest annual swing landed in 2021, when Current Deferred Revenue surged 3092041.43%; it then sank 100.0% in 2022.
• Tracing NBP's Current Deferred Revenue over 5 years: stood at $556172.6 in 2019, then surged by 103.72% to $1.1 million in 2020, then soared by 3092041.43% to $35.0 billion in 2021, then sank by 100.0% to $1.2 million in 2022, then tumbled by 74.96% to $305552.3 in 2023.
• Per Business Quant, the three latest NBP Current Deferred Revenue figures stand at $305552.3 (Q4 2023), $1.5 million (Q2 2023), and $1.2 million (Q4 2022).

Peer Comparison